Loading, Please Wait...
WALTHAM, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Avedro, Inc. (Nasdaq: AVDR) (“Avedro”), a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses, today reported financial results for the quarter and full year ended December 31, 2018.
"We are pleased with our 2018 performance which was characterized by several critical accomplishments which provide the foundation for our corneal cross-linking treatment to be widely available across the United States,” said Reza Zadno, President and CEO. “With widespread reimbursement, market exclusivity, meaningful commercial expansion, and strong patient enrollment in our clinical trials – we continue our journey to help a large underserved market with our clinically proven minimally invasive corneal cross-linking products.”
Fourth Quarter Financial Results
Revenue for the quarter ended December 31, 2018, increased 82% to $8.2 million, from $4.5 million during the same period in 2017. The increase in revenue was primarily driven by an increase in U.S. revenue which amounted to $3.2 million, and by a $0.5 million increase in non-U.S. revenue.
Gross margin was 67.6% for the fourth quarter of 2018, as compared to 40.3% in the same period in 2017.
Operating expenses were $10.2 million for the fourth quarter of 2018, as compared to $7.7 million in the same period in the prior year. This 32.0% year over year increase in operating expenses was driven by an increase in sales and marketing expenses due to the hiring of new salespeople and reimbursement personnel and an increase in research and development expenses from Avedro’s ongoing clinical trials.
Operating loss was $4.7 million in the fourth quarter of 2018, as compared to $5.9 million in the same period in 2017.
Net loss was $6.4 million in the fourth quarter, as compared to $6.7 million in the same period in 2017.
Full Year 2018 Financial Results
Revenue for the year ended December 31, 2018, increased 37% to $27.7 million, from $20.2 million in 2017. The increase in revenue was primarily driven by an increase in U.S. revenue which amounted to $7.8 million, offset by a $0.3 million decrease in non-U.S. revenue.
Gross profit for the year was $16.8 million, or 60.7% gross margin, up from $10.3 million, or 51.1% gross margin in 2017.
Operating expenses for the year were $38.0 million, an increase of 29.9% compared to 2017. The increase in operating expenses was driven by an increase in sales and marketing expenses due to the hiring of new salespeople and reimbursement personnel and an increase in research and development expenses from Avedro’s ongoing clinical trials.
Net loss for 2018 was $25.1 million, as compared with net loss of $21.3 million in 2017.
Cash and cash equivalents were $9.8 million as of December 31, 2018.
Guidance for Full Year 2019
Avedro expects revenue for the full year to be in the range of $36 million to $40 million, representing annual growth of approximately 37% at the midpoint of the range.
Webcast and Conference Call Information
Avedro’s management team will host a conference call today beginning at 4:30 p.m. ET. Investors interested in listening to the conference call may do so by dialing (866) 951-6741 for domestic callers or (409) 216-0623 for international callers, using Conference ID: 4287595. A live and archived webcast of the event will be available on the “Investors” section of Avedro’s website at www.avedro.com.
About Avedro, Inc.
Avedro is a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses. Avedro’s proprietary Corneal Remodeling Platform is designed to strengthen, stabilize and reshape the cornea utilizing corneal cross-linking in minimally invasive and non-invasive outpatient procedures to treat corneal ectatic disorders and correct refractive conditions. The Avedro Corneal Remodeling Platform is comprised of Avedro’s KXL and Mosaic systems, each of which delivers ultraviolet A light, and a suite of proprietary single-use riboflavin drug formulations, which, when applied together to the cornea, induce a biochemical reaction called corneal collagen cross-linking.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about Avedro’s financial condition and results of operations, payor and coverage and payment policies and Avedro’s future financial performance for the full year 2019. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “anticipates,” and “future” or similar expressions are intended to identify forward-looking statements. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of risks and uncertainties and other important factors, any of which could cause Avedro’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in Avedro’s prospectus dated February 13, 2019 filed pursuant to Rule 424(b)(4) as well as discussions of potential risks, uncertainties and other important factors in Avedro’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Avedro undertakes no duty to update this information unless required by law.
Greg Chodaczek or Lynn Lewis
|Condensed Statement of Operations|
|(in thousands, except per share data)|
|Three Months Ended||Twelve Months Ended|
|December 31,||December 31,|
|Cost of goods sold||2,656||2,693||10,879||9,850|
|Selling, general and administrative||7,004||4,982||25,999||18,991|
|Research and development||3,217||2,761||12,043||10,286|
|Total operating expenses||10,221||7,743||38,042||29,277|
|Loss from operations||(4,672||)||(5,927||)||(21,249||)||(18,973||)|
|Other income (expense), net||(1,740||)||(750||)||(3,873||)||(2,304||)|
|Net loss per share, basic and diluted||$||(17.97||)||$||(16.12||)|
|Weighted average common shares|
|used to compute net loss per share,|
|basic and diluted||1,398,065||1,319,542|
|Condensed Balance Sheet|
|Cash & cash equivalents||$||9,769||$||8,850|
|Accounts receivable, net||4,725||3,239|
|Prepaid expenses and other current assets||1,919||2,169|
|Total current assets||20,672||19,409|
|Equipment and furniture, net||1,524||1,640|
|Other non-current assets||3,671||647|
|Liabilities, convertible preferred stock and stockholders' deficit|
|Accrued expenses and other current liabilities||6,304||4,022|
|Total current liabilities||8,430||6,902|
|Other non-current liabilities||2,663||1,354|
|Convertible preferred stock||68,423||43,641|
|Total liabilities, convertible preferred stock and stockholders' deficit||$||25,867||$||21,696|